Trial
NCT04785924
Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Wake Forest University Health Sciences
Collaborators
Merck Sharp & Dohme LLC
Condition
Carbapenem-Resistant Enterobacteriaceae Infection
Intervention
Imipenem+Relebactam
Why stopped
Lack of enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-04